Therapeutic Potentials and Candidates for COVID-19
Abstract The current coronavirus disease 2019 (COVID-19) outbreak spread rapidly worldwide. Yet, there is no identifiable antiviral treatment, so an effective drug is urgently needed. Preventive strategies and oxygen therapy are the main practical approaches to prevent and treat COVID-19. Clinical trials are in progress for the antiviral and immunomodulation agents that eventually are being developed for COVID-19 treatment. Pharmacological, immunotherapies, natural-based supplements, biologics, and combination therapies interventions have been established. The concept of drug repurposing was re-visited, and many conventional antivirals or immunosuppresses were evaluated for Efficacy against COVID-19 infection. Even though much has been published, the rapid progression of therapeutic strategies and unpredictable disease alterations necessitates continual information updates. This review defines drug repurposing and summarizes a medication developed for other therapeutic approaches rather than SARS-CoV-2 treatment. Furthermore, we provide data on the effectiveness of traditional Chinese medicines (TCM) on COVID-19. Additionally, biological and advanced Nano-based drug delivery systems are reviewed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Iranian journal of science and technology - 47(2023), 4 vom: 17. Juli, Seite 1283-1297 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rezghi Rami, Mina [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Shiraz University 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s40995-023-01488-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052833828 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052833828 | ||
| 003 | DE-627 | ||
| 005 | 20230823064731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230823s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40995-023-01488-6 |2 doi | |
| 035 | |a (DE-627)SPR052833828 | ||
| 035 | |a (SPR)s40995-023-01488-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rezghi Rami, Mina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Potentials and Candidates for COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Shiraz University 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract The current coronavirus disease 2019 (COVID-19) outbreak spread rapidly worldwide. Yet, there is no identifiable antiviral treatment, so an effective drug is urgently needed. Preventive strategies and oxygen therapy are the main practical approaches to prevent and treat COVID-19. Clinical trials are in progress for the antiviral and immunomodulation agents that eventually are being developed for COVID-19 treatment. Pharmacological, immunotherapies, natural-based supplements, biologics, and combination therapies interventions have been established. The concept of drug repurposing was re-visited, and many conventional antivirals or immunosuppresses were evaluated for Efficacy against COVID-19 infection. Even though much has been published, the rapid progression of therapeutic strategies and unpredictable disease alterations necessitates continual information updates. This review defines drug repurposing and summarizes a medication developed for other therapeutic approaches rather than SARS-CoV-2 treatment. Furthermore, we provide data on the effectiveness of traditional Chinese medicines (TCM) on COVID-19. Additionally, biological and advanced Nano-based drug delivery systems are reviewed. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Coronavirus disease 2019 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Treatment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug repurposing |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Meskini, Maryam |4 aut | |
| 700 | 1 | |a Rezaei Khozani, Nahid |4 aut | |
| 700 | 1 | |a Forouzandehdel, Shayan |4 aut | |
| 700 | 1 | |a Momtaz, Saeideh |4 aut | |
| 700 | 1 | |a Ghosh, Soumya |4 aut | |
| 700 | 1 | |a Rezaei, Nima |4 aut | |
| 700 | 1 | |a Abdolghaffari, Amir Hossein |0 (orcid)0000-0001-9961-9097 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Iranian journal of science and technology |d Cham, Switzerland : Springer International Pubishing, 2004 |g 47(2023), 4 vom: 17. Juli, Seite 1283-1297 |w (DE-627)SPR038034816 |w (DE-600)2843077-3 |x 2364-1819 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2023 |g number:4 |g day:17 |g month:07 |g pages:1283-1297 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40995-023-01488-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2023 |e 4 |b 17 |c 07 |h 1283-1297 | ||